Clinical-stage medical device company CereVasc recently celebrated the opening of a new manufacturing and research facility in Wilmington as the company prepares for the commercialization of its investigational eShunt® System. Massachusetts Economic Development Secretary Eric Paley and Massachusetts Life Sciences Center (MLSC) President and CEO Kirk Taylor, MD, joined company leadership for the ribbon-cutting ceremony, recognizing the company’s continued growth and investment in the Commonwealth.
The new facility includes an ISO Class 7 clean room designed to support manufacturing, testing, assembly, and research activities as CereVasc advances its eShunt System. The technology is designed to provide a minimally invasive alternative to conventional shunt surgery for communicating hydrocephalus, including normal pressure hydrocephalus, a serious and often underrecognized condition caused by a buildup of cerebrospinal fluid that can disrupt normal brain function.
“This facility is an investment in CereVasc’s future,” said Dan Levangie, chairman and CEO of CereVasc. “It expands the capabilities we’ll need as we prepare for potential commercialization of the eShunt System, supports our long-term growth and helps position us to bring this innovation to patients. We’re proud to continue building CereVasc in Massachusetts, where the life sciences community continues to fuel innovation.”
This expansion was supported through a Tax Incentive award of $204,000 from the MLSC in 2025, helping CereVasc expand its workforce and increase capabilities in the Commonwealth.
